黃浩杰
個人簡介
浙江大學求是講席教授,，浙大第一醫(yī)院泌尿醫(yī)學科學與技術(shù)研究所所長,。原美國梅奧醫(yī)學中心Gordon H and Violet Bartels講席教授,、梅奧基礎(chǔ)泌尿研究中心主任、梅奧癌癥中心癌癥基因組-信號傳導-細胞轉(zhuǎn)移研究方向共同負責人,，曾任美國基礎(chǔ)泌尿研究學會（SBUR）主席,。是前列腺癌研究領(lǐng)域國際頂級專家，在腫瘤轉(zhuǎn)錄組學,、表觀遺傳學,、治療抗性和新藥研發(fā)等方向取得了一系列突破性重大成果，以通訊或第一作者在Science,、 Nature Medicine,、Cancer Cell,、 Nature Cell Biology、 Molecular Cell,、 Science Advances等雜志上發(fā)表高質(zhì)量論文170多篇,，h-指數(shù)62。作為課題首席科學家（PI）,，承擔美國國立衛(wèi)生研究院（NIH）R01基金9項,，美國國防部（DOD）前列腺癌研究項目3項和美國前列腺癌癥基金會（PCF）課題1項，累計獲得科研資助2200余萬美元,。作為第一發(fā)明人,，申請US/PCT專利31項、授權(quán)4項,，并有兩項研究已進入多中心二期臨床試驗,。
代表性成果
1.Sun R, Yan B, Li H, Ding D, Wang L, Pang J, Ye D, Huang H. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res. 2023 Oct 2; 83 (19):3192-3204
2.Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discov. 2023 Sep 7 Epub 2023 Sept 07
3.Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat Commun. 2023 Aug 3; 14 (1):4671 Epub 2023 Aug 03
4.Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, Jimenez R, Chen S, Cui XL, Zou Z, Yue Z, Emch MJ, Hawse JR, Wang L, He HH, Xia S, Han B, He C, Huang H. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 Aug 3; 83 (15):2692-2708.e7 Epub 2023 July 20
5.Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li LL, Wang B, Yan Y, Pan Y, Ye Q, Liu T, Feng X, Xu S, Wang K, Wang X, Jian Y, Ma B, Fan Y, Gao Y, Huang H, Li L. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. Nat Commun. 2023 Mar 31; 14(1):1810.
6. Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, Jimenez R, Chen S, Cui XL, Zou Z, Yue Z, Emch MJ, Hawse JR, Wang L, He HH, Xia S, Han B, He C, Huang H. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 Aug 3; 83 (15):2692-2708.e7 Epub 2023 July 20
7. Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat Commun. 2023 Aug 3; 14 (1):4671 Epub 2023 Aug 03
8. Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li LL, Wang B, Yan Y, Pan Y, Ye Q, Liu T, Feng X, Xu S, Wang K, Wang X, Jian Y, Ma B, Fan Y, Gao Y, Huang H, Li L. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. Nat Commun. 2023 Mar 31; 14(1):1810.
9. Orme JJ, Mer G, Huang H. Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM. Mol Cell 2023 Mar 2; 83 (5):655-656
10. Ding D, Zheng R, Tian Y, Jimenez R, Hou X, Weroha SJ, Wang L, Shi L, Huang H. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat Commun. 2022 Oct 23; 13 (1):6311
11. Sun R, Wei T, Ding D, Zhang J, Chen S, He HH, Wang L, Huang H. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2022 Sep 27; 119 (39):e2205509119 Epub 2022 Sept 21
12. Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nat Commun. 2021 Oct 1; 12 (1):5779 Epub 2021 Oct 01
13. Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li HY, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Adv Sci (Weinh). 2021 Oct; 8 (20):e2102555 Epub 2021 Aug 16
14. Zhang J, Gao K, Xie H, Wang D, Zhang P, Wei T, Yan Y, Pan Y, Ye W, Chen H, Shi Q, Li Y, Zhao SM, Hou X, Weroha SJ, Wang Y, Zhang J, Karnes RJ, He HH, Wang L, Wang C, Huang H. SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nat Commun. 2021 Sep 29; 12 (1):5716 Epub 2021 Sept 29
15. He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021 Jul 15; 131(14).
16. Wang D, Ma J, Botuyan MV, Cui G, Yan Y, Ding D, Zhou Y, Krueger EW, Pei J, Wu X, Wang L, Pei H, McNiven MA, Ye D, Mer G, Huang H. ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. Sci Adv. 2021 Jun; 7 (25) Epub 2021 June 18
17. He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021 Mar 9; 12 (1):1521 Epub 2021 Mar 09
18. Tang B, Sun R, Wang D, Sheng H, Wei T, Wang L, Zhang J, Ho TH, Yang L, Wei Q, Huang H. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A. 2021 Feb 23; 118 (8)
19. Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, Pan Y, Hou X, Weroha SJ, Karnes RJ, Wang D, Wu Q, Wu D, Huang H. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3? and WEE1. Mol Cell. 2020 Sep 17; 79(6):1008-1023.e4. Epub 2020 Aug 31.
20. Orme JJ, Huang H. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Cancer Cell 2020 Aug 10; 38 (2):155-157
21. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019 Jan 3; 73 (1):22-35.e6 Epub 2018 Dec 06
22. Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z, Jimenez R, Wang L, Wu H, Huang H. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Mol Cell. 2018 Aug 16; 71 (4):592-605.e4 Epub 2018 July 26
23. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017 Sep; 23 (9):1055-1062 Epub 2017 Aug 14
24. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J, Sun Y, Huang H. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell. 2015 Sep 17; 59 (6):904-16 Epub 2015 Sept 03
25. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014 Feb 27; 6 (4):657-69 Epub 2014 Feb 06
26. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010 Nov; 12(11):1108-14. Epub 2010 Oct 10.
27. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006 Oct 13; 314 (5797):294-7
